@entity6955 for diuretic treatment of advanced XXXX .

@entity1 @entity3747 @entity1369 @entity4 @entity1483 @entity1372 @entity6955 @entity177 @entity460 @entity916
In a double-blind randomized clinical trial the efficacy and safety of oral high-dose @entity6955 ( @entity6955 , T) therapy was compared with that of @entity1483 (F) in 10 @entity1 with advanced @entity177 . The efficacy on @entity4 , fluid and electrolyte balance including the influence on @entity916 -angiotensin- @entity1369 system and cochlear function was evaluated. @entity1 were randomly allocated to either 500 mg F/d (group 1) or 200 mg T/d (group 2). After 14 days of treatment doses were doubled in each group for further 14 days. With respect to the 2.5 times lower dose of T the clinical effect of both drugs on @entity4 , fluid and @entity1372 excretion was equipotent. Significant differences were noted on calciuresis. Serum @entity460 levels were reduced with F, while T had no influence on @entity460 balance. A significant increase in plasma @entity916 activity (PRA) was observed after F, whereas T had no raising effect on PRA. No significant alteration of plasma @entity1369 concentration occurred with T or F. No adverse effects were noted in both groups. Serial audiometries showed no significant impairment of cochlear function with both drugs. In conclusion, these results indicate that high-dose T is efficient and safe in the treatment of advanced @entity177 . The lack of a calciuric effect with T can be regarded as an advantage in @entity1 with @entity3747 in @entity177 .
